Health tech startup Signos announced a $20 million funding round, which will help it strengthen its position in the weight loss market driven by GLP-1 medications. The funding comes from notable investors including Google Ventures, Dexcom, and Blue Cross Blue Shield of Alabama, and includes a distribution deal that will feature Signos' subscription plans on Dexcom's direct-to-consumer platform.
CEO Sharam Fouladgar-Mercer emphasized the collaboration with Dexcom reflects a shared vision for glucose biosensing technology beyond diabetes management. Signos has developed an AI-powered glucose monitoring system, the first of its kind approved by the FDA, which utilizes Dexcom's continuous glucose monitor to provide real-time insights into how lifestyle choices impact health.
The platform offers personalized recommendations to help users adopt healthier habits. The new funding will also support the expansion of predictive AI features, such as meal scoring, which alerts users about potential glucose spikes from specific foods.
Fouladgar-Mercer noted that the service is designed for individuals looking to enhance their GLP-1 treatments or as a standalone weight loss solution. With obesity affecting nearly 74% of Americans, and projections indicating that 25 million will be using GLP-1 drugs by 2030, Signos' partnership with Dexcom positions it well in a rapidly growing market.
Although the company did not disclose its valuation, Fouladgar-Mercer reported a tenfold increase in both revenue and user base over the past six months, with many participants in clinical studies. He highlighted the importance of tracking metabolic responses to effectively support behavior change in users